Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma
Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma
复制标题
DOI：
10.1016/j.ejca.2013.06.002
复制
发表时间：
2013-11-01
影响因子：
8.4
通讯作者：
Waidmann, Oliver
中科院分区：
文献类型：
--
作者：
Koeberle, Verena;Kronenberger, Bernd;Waidmann, Oliver
背景：寻找新的生物标志物来预测肝细胞癌（HCC）的侵袭性，并补充现有的预后和治疗算法是一项重要的临床需求。血液循环中的细胞外微rna （miRNAs）是一类极具前景的新型疾病标志物。目的：本研究探讨HCC患者血清中miR-1和miR-122的预后潜力。方法：从纳入研究时获得的195例HCC患者和54例肝硬化患者的血清中提取RNA。miR-1和miR-122水平与总生存期（OS）、肝癌意大利计划（CLIP）评分、巴塞罗那临床肝癌分期、临床化学参数和肿瘤特异性治疗相关。结果：血清miR-1和miR-122水平较高的患者比血清miR-1和miR-122浓度较低的患者的OS更长（风险比[HR] 0.440, 95%可信区间[CI] 0.233-0.831， miR-1的P = 0.011；风险比[HR] 0.493, 95% CI 0.254-0.956， miR-122的P = 0.036）。血清miR-1和miR-122浓度在HCC和肝硬化患者之间无显著差异。一项年龄、性别、肿瘤分期和治疗调整后的多因素Cox回归分析显示，miR-1血清水平（HR 0.451, 95% CI 0.228-0.856, P = 0.015）与OS独立相关，而miR-122血清水平与OS无关。血清miR-1水平与肝脏临床化学参数无相关性，血清miR-122水平与肝坏死炎症、肝功能、合成能力的临床化学参数相关。结论：我们的数据表明，血清miR-1是HCC患者OS的一个新的独立参数，因此可能提高经典HCC分期评分的预测价值。(C) 2013 Elsevier Ltd.版权所有。
Background: The identification of new biomarkers to predict the aggressiveness of hepatocellular carcinoma (HCC) and supplement the current set of prognosis and treatment algorithms is an important clinical need. Extracellular microRNAs (miRNAs) circulating in the blood are a new class of highly promising disease markers.Aim: Here we investigated the prognostic potential of miR-1 and miR-122 in sera from patients with HCC.Methods: RNA was extracted from 195 sera of HCC patients and 54 patients with liver cirrhosis, obtained at the time of study enrolment. miR-1 and miR-122 levels were correlated with overall survival (OS), Cancer of the Liver Italian Program (CLIP) score, Barcelona Clinic Liver Cancer stage, clinical chemistry parameters and tumor specific treatment.Results: Patients with higher miR-1 and miR-122 serum levels showed longer OS than individuals with lower miR-1 and miR-122 serum concentrations (hazard ratio [HR] 0.440, 95% confidence interval [CI] 0.233-0.831, P = 0.011 for miR-1 and HR 0.493, 95% CI 0.254-0.956, P = 0.036 for miR-122, respectively). Serum miR-1 and miR-122 concentrations did not differ significantly between patients with HCC and liver cirrhosis. An age-, sex-, tumor stage and treatment-adjusted multivariate Cox regression analysis revealed that miR-1 serum levels (HR 0.451, 95% CI 0.228-0.856, P = 0.015) were independently associated with OS, whereas serum miR-122 was not. miR-1 serum levels showed no relevant correlation with clinical chemistry liver parameters, whereas serum miR-122 correlated with clinical chemistry parameters of hepatic necroinflammation, liver function and synthetic capacity.Conclusion: Our data indicate that serum miR-1 is a new independent parameter of OS in HCC patients and may therefore improve the predictive value of classical HCC staging scores. (C) 2013 Elsevier Ltd. All rights reserved.